Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Aripiprazole 10 mg vs Abilify in Healthy Adults
NCT05532254Phase 1Completed
- Sponsor
- Future University in Egypt
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aripiprazole in schizophrenia and bipolar disorder (BD) (2 arms), sponsored by Future University in Egypt. Primary endpoints: Maximum Plasma Concentration and Area Under the Plasma Concentration Curve (0-72h). Started Feb 2021; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT05532254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532254.